Nov 29, 2023 / 05:55PM GMT
Unidentified Analyst -
Thank you guys for being here. Pleasure to have a management team from Roivant join us. You guys have a lot of cash, what you're planning on doing?
Matthew Gline - Roivant Sciences Ltd. - CEO & Director
We do -- look, post the deal close, we will have roughly $7 billion. I think, look, that's an incredibly privileged place to be. In this interest rate environment, getting over 5% interest on that is not a bad place to be. And the deal hasn't closed. We said it's going to close towards the end of this year or beginning of next year, so don't have it yet. But look, we have -- our burn is roughly, what, 200 a quarter or so. We're spending that on the VTAMA launch and a lot of multiple late-stage clinical programs, we just had fantastic data on 1402 for an Anti-FcRn asset, that can obviously go pretty broad in terms of indications and there's a lot of things out there to be done in terms of deals, right?
I think, look, big pharma is going through a very unique period right now where there's a lot of EPS pressure and there's deals to be
Roivant Sciences Ltd at Evercore ISI HealthCONx Conference Transcript
Nov 29, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers